Mineralys Therapeutics held its 2026 annual meeting of stockholders on May 21, 2026. Stockholders elected Srinivas Akkaraju, Brian Taylor Slingsby, and Daphne Karydas as Class III directors for a three-year term expiring in 2029. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 72,648,272 votes in favor.